North America Fabry Disease Treatment Market Size & Outlook
North America fabry disease treatment market, 2016-2027 (US$M)
Related Markets
North America fabry disease treatment market highlights
- The North America fabry disease treatment market generated a revenue of USD 602.3 million in 2020.
- The market is expected to grow at a CAGR of 4.1% from 2021 to 2027.
- In terms of segment, fabrazyme was the largest revenue generating product in 2020.
- Galafold is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2021 to 2027.
North America data book summary
| Market revenue in 2020 | USD 602.3 million |
| Market revenue in 2027 | USD 799.8 million |
| Growth rate | 4.1% (CAGR from 2020 to 2027) |
| Largest segment | Fabrazyme |
| Fastest growing segment | Galafold |
| Historical data covered | 2016 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Galafold, Fabrazyme, Replagal |
| Key market players worldwide | 3D Systems Corp, Formlabs, Voxeljet AG ADR |
Other key industry trends
- In terms of revenue, North America region accounted for 49.8% of the global fabry disease treatment market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2027.
- MEA is the fastest growing regional market and is projected to reach USD 21.0 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Fabry Disease Treatment Market Scope
Fabry Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America fabry disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fabry disease treatment market will help companies and investors design strategic landscapes.
Fabrazyme was the largest segment with a revenue share of 86.05% in 2020. Horizon Databook has segmented the North America fabry disease treatment market based on galafold, fabrazyme, replagal covering the revenue growth of each sub-segment from 2016 to 2027.
The U.S. is anticipated to be the most lucrative market in North America owing to the presence of a large target population, high awareness regarding easy diagnosis & treatment of Fabry Disease, and implementation of newborn screening programs for Fabry Disease in most of the states of the country.
The USA is the biggest market for the Fabry Disease Therapeutics with growing awareness about the disease, enforcement of newborn screening in the many states, investment in the research and development of rare disease disorders, and supporting government policies.
The growth of the Canadian market can primarily be attributed to increasing healthcare expenditure, leading to advancements in healthcare infrastructure. Furthermore, ongoing public-private initiatives and growing awareness about Fabry Disease in the country have created significant opportunities for market growth.
Reasons to subscribe to North America fabry disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America fabry disease treatment market databook
-
Our clientele includes a mix of fabry disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America fabry disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into North America fabry disease treatment market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
North America fabry disease treatment market size, by country, 2016-2027 (US$M)
North America Fabry Disease Treatment Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
